Research into Friedreich ataxia has been hampered by low availability of study participants. Now, a European consortium has released baseline data from a continuing study of 592 patients with Friedreich ataxia, providing information on clinical features and progression. Such large cooperative studies might herald the final battle against this disabling disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Friedreich ataxia in Norway – an epidemiological, molecular and clinical study
Orphanet Journal of Rare Diseases Open Access 04 September 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Campuzano, V. et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423–1427 (1996).
Reetz, K. et al. Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 14, 174–182 (2015).
Schmucker, S. & Puccio, H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum. Mol. Genet. 19, R103–R110 (2010).
Saccà, F. et al. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS ONE 6, e17627 (2011).
Filla, A. et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet. 59, 554–560 (1996).
Dürr, A. et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 1169–1175 (1996).
Pandolfo, M. et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76, 509–521 (2014).
Parkinson, M. H., Schulz, J. B. & Giunti, P. Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J. Neurochem. 126 (Suppl. 1), 125–141 (2013).
Soragni, E. et al. Epigenetic therapy for Friedreich ataxia. Ann. Neurol. 76, 489–508 (2014).
Plasterer, H. L. et al. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia. PLoS ONE 8, e63958 (2013).
Acknowledgements
The authors would like to thank Josh Williams for checking the English in the article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
De Michele, G., Filla, A. Friedreich ataxia today—preparing for the final battle. Nat Rev Neurol 11, 188–190 (2015). https://doi.org/10.1038/nrneurol.2015.33
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.33
This article is cited by
-
The Working Life of People with Degenerative Cerebellar Ataxia
The Cerebellum (2019)
-
Genome engineering: a new approach to gene therapy for neuromuscular disorders
Nature Reviews Neurology (2017)
-
Friedreich ataxia in Norway – an epidemiological, molecular and clinical study
Orphanet Journal of Rare Diseases (2015)